Primary Care Management of CKD - Simulation-based activities

Primary Care Management of CKD - Simulation-based activities is organized by Springer Healthcare IME.

About the program:

Nearly 850 million people worldwide are affected by CKD with up to an estimated 97% of these patients remaining undiagnosed. With much of the identification burden falling to primary care physicians, you need to be aware of all known risk factors and the latest diagnostic guidelines to proactively screen for CKD, identify patients at risk, and accurately diagnose and manage this progressive condition.

This independent educational program will provide decision-making support and educational tools to guide practitioners in a real-world clinical context. Patient profiles are presented as simulated scenarios to assist your decision-making in a risk-free environment, enhanced with expert-led discussion and commentary.

Simulation-Based Activities:

A series of four simulation-based activities provide a practical and safe setting to test your diagnostic capabilities and management decisions in realistic CKD scenarios you may face in your daily practice. Each video scenario looks at different complexities you are likely to face in the management of CKD, considering common comorbidities and patient preferences.

The scenarios are supplemented by a downloadable infographic with the key signs and pitfalls to look out for in patient consultations to ensure early intervention and effective management of CKD.

Learning objectives:

PCPs participating in the program will be able to:

• Apply the most recent classification and staging guidelines to achieve earlier diagnosis of CKD
• Describe how to manage the initial complications and risks associated with a CKD diagnosis, including when to refer to another member of the specialist MDT
• Incorporate guidelines and evidence-based tools into everyday practice to appropriately manage different CKD patient profiles

Target audience: The program is intended for global primary care practitioners. All content will be available in French, Spanish, German, Italian, and Portuguese. The infographic and video will be translated into Japanese and simplified Chinese.

AstraZeneca has provided an educational grant towards this independent program.